{
  "docId": "019de075-4aec-72cf-a6e0-519f4b0af11c",
  "docSlug": "80e6ab6db3df4d91b63f99a2a4cf6dc3",
  "documentTitle": "Exscientia | Investor Presentation Deck | 73 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 73,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 43,
  "notes": "The slide displays a heatmap of 43 patient samples showing ABS scores, signature scores, and cancer diagnoses.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4aec-72cf-a6e0-519f4b0af11c/31",
  "deckHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c",
  "deckJsonHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c.json",
  "deckAnchorHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.75,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "chart",
      "text": "43 Example Patient Samples heatmap",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d5ee6a6-f56e-4b36-bcd2-cd5aae958dd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.1,
        "y": 0.76
      },
      "kind": "list",
      "text": "Expected to enrich patients more likely to respond to adenosine-pathway inhibition\nSupported with biological validation including soluble factor data\nExscientia’s ABS is differentiated from other published “adenosine signatures”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c305ac2-7d9a-46fb-a1f0-9de9ee466c50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.67
      },
      "kind": "paragraph",
      "text": "Exscientia's ‘546 response signature, the adenosine burden score (ABS), was developed using single cell transcriptomics of primary samples after ex vivo perturbation with stabilised adenosine",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b98e3159-5a6d-4ec9-b5d4-5853fdf94015",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Vladimer et al, ESMO I-O (2022)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d5531dc-9c3b-4464-b4ab-851fa7cbf014",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.14
      },
      "kind": "title",
      "text": "Developed novel adenosine-pathway activity signature",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9af5278e-2b69-4e64-97c5-f6ec288f6a63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Enriching for patients that will benefit most from ‘546",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebb1b250-c204-4b44-bbe5-558f8f2d6be7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "713b0f05-f426-4900-8d20-91458fc7c275",
      "evidence": "Enriching for patients that will benefit most from ‘546",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "93853e4f-bc56-4e9b-bf60-81f8e6d985d5",
      "evidence": "Expected to enrich patients more likely to respond to adenosine-pathway inhibition",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "02ebf716-8af1-4eca-8937-1321b5d2471c",
      "evidence": "The deck presents the consequences of not adopting Exscientia's technology throughout the presentation",
      "position": 0,
      "objective": "What is the cost of not adopting Exscientia's AI-driven precision medicine platform?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 72,
      "from": 29,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c1ff2e13-046f-4a68-9f90-d544bd3e6de9",
      "evidence": "The deck presents information on Exscientia's clinical stage compounds and their potential benefits",
      "position": 1,
      "objective": "What are the potential benefits of Exscientia's clinical stage compounds?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}